Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

Posted: December 2, 2022 at 12:43 am

HEIDELBERG, Germany,, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host an Investor Event on December 10 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Read the original post:
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

Related Posts